Target Population
Patients with resectable oesophageal adenocarcinoma (OAC) recommended for neoadjuvant chemotherapy. Additionally, the VISTA trial focuses on target populations with specific HLA type for each Phase as described below:
Phase I Safety Lead-in: HLA A*02:01
Phase II Randomised trial: At least one or more of HLA A*02:01, HLA B*07:02 or HLA B*40:01
(Detailed eligibility criteria mentioned below)
